CONFIDENTIAL VIA EMAIL December 31 2018 Garrison J. Hasara, CPA c/o HedgePath Pharmaceuticals, Inc. Tampa, Florida 33606HedgePath Pharmaceuticals, Inc. • December 31st, 2018 • Services-commercial physical & biological research • Delaware
HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as set forth below. This letter is referred to herein as the “Letter Agreement.” This Letter Agreement replaces your employment agreement with the Company, dated September 4, 2014, as amended (the “Previous Agreement”), which agreement as you know shall expire on December 31, 2018.
CONFIDENTIAL VIA EMAIL December 31, 2018 Mr. Nicholas J. Virca c/o HedgePath Pharmaceuticals, Inc. Tampa, Florida 33606Letter Agreement • December 31st, 2018 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as set forth below. This letter is referred to herein as the “Letter Agreement.” This Letter Agreement replaces your employment agreement with the Company, dated June 24, 2014, as amended (the “Previous Agreement”), which agreement as you know shall expire on December 31, 2018.
